Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Up 133.6% in March

Azitra, Inc. (NYSEAMERICAN:AZTR) was the target of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 102,100 shares, an increase of 133.6% from the February 29th total of 43,700 shares. Based on an average trading volume of 418,500 shares, the days-to-cover ratio is presently 0.2 days. Currently, 1.5% of the shares of the stock are short sold.

Azitra Price Performance

Shares of NYSEAMERICAN AZTR remained flat at $0.21 during trading hours on Friday. The stock had a trading volume of 231,570 shares, compared to its average volume of 322,775. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.58 and a current ratio of 1.58. Azitra has a 52-week low of $0.18 and a 52-week high of $5.18.

Insiders Place Their Bets

In other news, CEO Francisco D. Salva acquired 333,300 shares of Azitra stock in a transaction on Tuesday, February 13th. The shares were acquired at an average price of $0.30 per share, with a total value of $99,990.00. Following the purchase, the chief executive officer now directly owns 338,300 shares in the company, valued at approximately $101,490. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders have bought a total of 351,600 shares of company stock valued at $105,480 in the last quarter.

Hedge Funds Weigh In On Azitra

Several large investors have recently modified their holdings of AZTR. Knollwood Investment Advisory LLC purchased a new position in Azitra during the 3rd quarter valued at $62,000. Citadel Advisors LLC purchased a new position in Azitra during the 2nd quarter valued at $57,000. Finally, Warberg Asset Management LLC boosted its holdings in Azitra by 20.7% during the 3rd quarter. Warberg Asset Management LLC now owns 35,000 shares of the company’s stock valued at $52,000 after acquiring an additional 6,000 shares during the period. Institutional investors own 11.16% of the company’s stock.

Azitra Company Profile

Azitra, Inc, a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S.